Table 1. Main characteristics of all the studies included in the meta-analysis.
| First author | Year | Study region | Primary site | Treatment | NO. (M/F) | Age | Follow-up(months) | N status(-/+) |
|---|---|---|---|---|---|---|---|---|
| Kusaba [27] | 2006 | Japan | colorectal | surgery | 66/42 | 65.6ys range:44–86ys | Median:43.7ms | 74/34 |
| Range:0.71–60ms | ||||||||
| Monnien [19] | 2010 | France | colorectal | surgery | 76/28 | Median: 66ys | >60ms | 67/31 |
| Morikawa [28] | 2011 | USA | colorectal | surgery | 266/458 | ≥65ys:454, <65ys:270 | Median: 129ms | NR |
| Dobi [14] | 2012 | France | colorectal | chemotherapy | 50/44 | ≤70ys:60, >70ys:34 | >120ms | NR |
| Yakata [29] | 2006 | Japan | gastric | surgery | 63/48 | Median:68.9ys | NR | 79/32 |
| Range:38–89ys | ||||||||
| Lee [15] | 2009 | Korea | gastric | surgery | 210/101 | Median: 53ys | >60ms | NR |
| Deng [30] | 2010 | China Mainland | gastric | surgery | 37/16 | Median:55ys | Median:35ms | NR |
| range:31–78ys | Range:4–85ms | |||||||
| Inokuchi [20] | 2011 | Japan | gastric | surgery | 88/38 | ≥70ys:41, <70ys:85 | 73ms | 59/76 |
| Woo [31] | 2011 | Korea | gastric | surgery | 193/92 | NR | Mean:51ms | 102/183 |
| Xiong [32] | 2012 | China Mainland | gastric | NR | 176/86 | Mean 59.3ys | Mean: 39.7ms | NR |
| Deng [33] | 2013 | China Mainland | gastric | surgery | 76/38 | Median:56.7ys | Median:38ms | 42/68 |
| Range:29–83ys | Range:2–108ms | |||||||
| Song [34] | 2014 | China Mainland | gastric | surgery | 46/14 | Median:60ys | Range:6–72ms | 0/60 |
| Wu [35] | 2014 | China Mainland | gastric | surgery | 43/17 | Mean:62ys | Median:23ms | NR |
| Range:37–90ys | Range:1–79ms | |||||||
| Zhang [16] | 2012 | Austria | hepatocellular | surgery | 80/20 | Mean:55.1ys | NR | NR |
| Range:28–77ys | ||||||||
| Wu [36] | 2011 | China Mainland | hepatocellular | surgery | 115/23 | ≤55ys:86,>55ys:52 | NR | NR |
| Mano [21] | 2013 | Japan | hepatocellular | surgery | 81/20 | positive 63.9±7.3ys | Median:1391days | NR |
| negative 63.6±9.5ys | Range:36–3289days | |||||||
| You [17] | 2011 | China Mainland | esophagus | surgery | 68/32 | 62.2±6.6ys | Median:16.8ms | NR |
| Range:0.8–69.2ms | ||||||||
| Schoppmann [37] | 2012 | Austria | esophagus | surgery | 253/72 | 63±10ys | 52ms | NR |
| Chen [22] | 2013 | Taiwan | esophagus | radiotherapy | 173 | NR | NR | 48/125 |
| Denley [18] | 2013 | UK | pancreatic | surgery | 43/43 | Median:64ys | NR | NR |
| Range:38–77ys | ||||||||
| Huang [23] | 2013 | China Mainland | pancreatic | surgery | 50/21 | Median:67ys | Mean:15.9ms | NR |
| Range:40–80ys | Range:1–101ms | |||||||
| Koperek [38] | 2013 | Caucasian | pancreatic | surgery | 48/31 | 66±11ys | 629±594days | NR |
| Study Cohort | Tumor differentiation (well or moderate/poor) | TNM(I+II/III+IV) | Antibody | Scoring Method | Cut-off | NO.of positive expression (%) | Survival analysis | HR |
| Kusaba [27] | 100/4 | NR | goat polyclonal antibody | E | 15% | 62(57.4%) | NR | R(M) |
| Monnien [19] | 97/1 | 0/104 | rabbit polyclonal antibody | E | 15% | 39(37.5%) | OS | R(M) |
| Morikawa [28] | NR | 384/301 | rabbit polyclonal antibody | I | NR | 131(18%,) | OS | R(M) |
| Dobi [14] | 362/0 | 19/75 | rabbit polyclonal antibody | E | 15% | 23(24.5%) | OS,DFS | R(M) |
| Yakata [29] | NR | NR | goat polyclonal antibody | E | 10% | 55(49.5%) | NR | R(M) |
| Lee [15] | 101/166 | 144/167 | rabbit polyclonal antibody | E | 1% | 79(26.1%) | OS,DFS | R(M) |
| Deng [30] | NR | NR | rabbit polyclonal antibody | E | 10% | 26(49.1%) | OS | R(M) |
| Inokuchi [20] | NR | NR | rabbit polyclonal antibody | E | 10% | 52(41%) | OS | R(M) |
| Woo [31] | NR | NR | NS | E | 1% | 103(36%) | NR | R(M) |
| Xiong [32] | 80/182 1+2/3+4 | 93/169 | NS | E | 15% | 136(51.9%) | OS | R(M) |
| Deng [33] | NR | NR | rabbit polyclonal antibody | EI | 25% | 89(78.07%) | OS | E(M) |
| Song [34] | 26/34 1+2/3 | 26/34 | rabbit polyclonal antibody | EI | 4 | 35(58.3%) | OS | R(M) |
| Wu [35] | NR | NR | NS | E | 5 | 26(43.3%) | NR | R(M) |
| Zhang [16] | 68/32 1+2/3+4 | 60/40 | mouse monoclonal antibody | E | 15% | 58(58%) | OS | R(M) |
| Wu [36] | NR | 106/31 | NS | E | 25% | 75(54.3%) | NR | R(M) |
| Mano [21] | 66/35 1+2/3 | NR | rabbit monoclonal antibody | E | 10.7% | 36(36%) | OS,DFS | R(M) |
| You [17] | 73/27 | 20/80 | rabbit polyclonal antibody | EI | 2 | 76(76%) | OS | R(M) |
| Schoppmann [37] | 183/141 | NR | rabbit monoclonal antibody | EI | 10 | 144(44.4%) | OS,DFS | R(M) |
| Chen [22] | NR | 45/128 | NS | EI | 2 | 82(47.4%) | OS,DFS | R(M) |
| Denley [18] | NR | NR | rabbit polyclonal antibody | EI | NR | 29(33.7%) | OS | R(M) |
| Huang [23] | 59/10 | 66/5 | rabbit polyclonal antibody | E | 5% | 39(54.9%) | OS | R(M) |
| Koperek [38] | 53/26 | NR | rabbit monoclonal antibody | E | 5% | 33 (41.8%) | NR | R(M) |
ms: months; ys: years; OS: overall survival; DFS: progression-free survival; HR: hazard ratio, obtained by reporting in text (R) or estimating (E). ‘‘M” means the HR come from multivariate analysis; E: extent; I: intensity; NR: not reported; NS: non-specific; Rabbit pAb: rabbit polyclonal antibody.